Clinical Responses in Patients With Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment With Risankizumab or Switching from Ustekinumab to Risankizumab. J of Skin 2017, 1 (3.1), s5. https://doi.org/10.25251/skin.1.supp.4.